PMID- 23588127
OWN - NLM
STAT- MEDLINE
DCOM- 20131112
LR  - 20220409
IS  - 1537-4521 (Electronic)
IS  - 0148-5717 (Print)
IS  - 0148-5717 (Linking)
VI  - 40
IP  - 5
DP  - 2013 May
TI  - Prevalence and treatment outcome of cervicitis of unknown etiology.
PG  - 379-85
LID - 10.1097/OLQ.0b013e31828bfcb1 [doi]
AB  - BACKGROUND: Mucopurulent cervicitis (MPC) is a clinical syndrome characterized by 
      mucopurulent discharge from the cervix and other signs of inflammation. This was 
      a phase III, multicenter study designed to evaluate the effectiveness of placebo 
      versus empiric antibiotic treatment for clinical cure of MPC of unknown etiology 
      at 2-month follow-up. Unfortunately, enrollment was terminated because of low 
      accrual of women with cervicitis of unknown etiology, but important prevalence 
      and outcome data were obtained. METHODS: Five hundred seventy-seven women were 
      screened for MPC. Women with MPC were randomized to the treatment or placebo arm 
      of the study, and the 2 arms were evaluated based on the etiology, clinical cure 
      rates, adverse events (AEs), and rates of pelvic inflammatory disease. RESULTS: 
      One hundred thirty-one (23% [131/577]) screened women were found to have MPC. 
      Eighty-seven were enrolled and randomized. After excluding women with sexually 
      transmitted infections and other exclusions, 61% (53/87) had cervicitis of 
      unknown etiology. The overall clinical failure rate was 30% (10/33), and the 
      clinical cure rate was only 24% (8/33). Rates were not significantly different 
      between the arms. There were 24 gastrointestinal AEs in the treatment arm 
      compared with 1 AE in the placebo arm. CONCLUSIONS: More than half of the cases 
      of MPC were of unknown etiology. Clinical cure rates for the placebo and 
      treatment arms were extremely low, with most women concluding the study with a 
      partial response. Gastrointestinal AEs were higher in the treatment arm.
FAU - Taylor, Stephanie N
AU  - Taylor SN
AD  - Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. 
      staylo2@lsuhsc.edu
FAU - Lensing, Shelly
AU  - Lensing S
FAU - Schwebke, Jane
AU  - Schwebke J
FAU - Lillis, Rebecca
AU  - Lillis R
FAU - Mena, Leandro A
AU  - Mena LA
FAU - Nelson, Anita L
AU  - Nelson AL
FAU - Rinaldi, Anne
AU  - Rinaldi A
FAU - Saylor, Lisa
AU  - Saylor L
FAU - McNeil, Linda
AU  - McNeil L
FAU - Lee, Jeannette Y
AU  - Lee JY
LA  - eng
GR  - N01AI40073/AI/NIAID NIH HHS/United States
GR  - Z99 NS999999/ImNIH/Intramural NIH HHS/United States
GR  - N01AI40073C/AI/NIAID NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Sex Transm Dis
JT  - Sexually transmitted diseases
JID - 7705941
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Mass Screening
MH  - Pelvic Inflammatory Disease/drug therapy/*epidemiology/etiology
MH  - Prevalence
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Uterine Cervicitis/*drug therapy/*epidemiology/etiology
MH  - Vaginosis, Bacterial/drug therapy/*epidemiology/etiology
PMC - PMC3868214
MID - NIHMS528606
EDAT- 2013/04/17 06:00
MHDA- 2013/11/13 06:00
PMCR- 2014/05/01
CRDT- 2013/04/17 06:00
PHST- 2013/04/17 06:00 [entrez]
PHST- 2013/04/17 06:00 [pubmed]
PHST- 2013/11/13 06:00 [medline]
PHST- 2014/05/01 00:00 [pmc-release]
AID - 00007435-201305000-00007 [pii]
AID - 10.1097/OLQ.0b013e31828bfcb1 [doi]
PST - ppublish
SO  - Sex Transm Dis. 2013 May;40(5):379-85. doi: 10.1097/OLQ.0b013e31828bfcb1.